Opdivo May Trigger Myasthenia Gravis, Case Report Indicates

Opdivo May Trigger Myasthenia Gravis, Case Report Indicates

Treatment with the immunotherapy Opdivo (nivolumab) may, in rare cases, trigger myasthenia gravis (MG), according to a Japanese case report. The patient, a 55-year-old woman, developed severe MG, which required admission to the intensive care unit and prolonged mechanical ventilation. The recovery of her breathing function was successfully monitored by assessing…

IVIG and Me: How Having a Port Has Improved My Treatments

One common treatment for myasthenia gravis (MG) is intravenous immunoglobulin (IVIG). I was initially treated with IVIG for my symptom flares and exacerbations. Thanks to detailed notes kept by my infusion nurses at the Veterans Affairs (VA) clinic in Maine, where I received those infusions, and because of…

Anti-thyroid Antibodies Tied to Specific Immune Profile in MG

Myasthenia gravis (MG) patients with antibodies against the thyroid gland have significantly more B-cells — the immune cells that produce antibodies — and fewer immune T-cells, a small single-center study in China shows. These early findings suggest the presence of anti-thyroid antibodies may affect the success of immunomodulating therapies…

Organizations Rally to Help Ukrainian Rare Disease Patients

A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…

Lymphoplasma Exchange Can Ease MG Symptoms in Flares, Study Finds

Lymphoplasma exchange — a procedure that involves exchanging a patient’s plasma and also removing certain immune cells from the bloodstream — can ease symptoms of acute exacerbations of myasthenia gravis (MG), a new study reports. The study, “Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study…

Ultomiris Is Approved in the US for Treating AChR-positive gMG

The long-acting complement inhibitor Ultomiris (ravulizumab-cwvz) has been approved by the U.S. Food and Drug Administration (FDA) to treat most adults with generalized myasthenia gravis (gMG). The approval specifically covers patients who are positive for antibodies against the acetylcholine receptor (AChR) — about 80% of gMG patients. “With the…

Risk Factors for MG Exacerbations, Myasthenic Crises ID’d in Study

Disease severity at diagnosis and levels of self-reactive antibodies are independent risk factors for myasthenic crisis and disease exacerbations, a German study suggests. Close monitoring, particularly of infections, is important to prevent disease worsening in people with myasthenia gravis (MG), the researchers noted. The study, “Independent risk factors…

My Dinner Plate Theory Helps Explain Daily Energy Levels

“Stick a fork in me, I’m done!” “I don’t have enough spoons for this.” We’ve all heard various quips involving silverware. When one becomes part of the chronic illness family, they may adopt the term “spoonie,” based on the spoon theory, a metaphor coined by lupus patient Christine Miserandino. Essentially,…